8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 30, 2026·SEC
Ultragenyx Pharmaceutical Inc.(RARE)Earnings, Financials & Key Ratios
RARE•NASDAQ
Price updated Jun 19, 2026
AboutUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.Show more
- Revenue$673M+20.1%
- EBITDA-$500M
- Net Income-$575M-1.0%
- EPS (Diluted)-5.83+7.3%
- Gross Margin83.8%-2.9%
- EBITDA Margin-74.29%+16.8%
- Operating Margin-79.49%+16.9%
- Net Margin-85.44%+15.9%
- ROE-607.51%-187.0%
RARE Key Insights
Ultragenyx Pharmaceutical Inc. (RARE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 19.9%
✗Weaknesses
- ✗Profits declining 25.2% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RARE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RARE Price & Volume
Ultragenyx Pharmaceutical Inc. (RARE) stock price & volume — 10-year historical chart
Loading chart...
RARE Growth Metrics
Ultragenyx Pharmaceutical Inc. (RARE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.95%
3 Years22.81%
TTM13.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3.91%
Return on Capital
10 Years-48.07%
5 Years-42.58%
3 Years-45.75%
Last Year-46.37%
RARE Recent Earnings
Ultragenyx Pharmaceutical Inc. (RARE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.84-23.7%
$1.49
Rev
$136M-14.0%
$158M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$1.29-7.5%
$1.20
Rev
$207M+4.2%
$199M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.81-47.2%
$1.23
Rev
$160M-19.9%
$200M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$1.17+7.9%
$1.27
Rev
$166M+0.3%
$166M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.84vs $1.49-23.7% | $136Mvs $158M-14.0% |
| Q1 2026 | Feb 12, 2026 | $1.29vs $1.20-7.5% | $207Mvs $199M+4.2% |
| Q4 2025 | Nov 4, 2025 | $1.81vs $1.23-47.2% | $160Mvs $200M-19.9% |
| Q3 2025 | Aug 5, 2025 | $1.17vs $1.27+7.9% | $166Mvs $166M+0.3% |
Based on last 12 quarters of dataView full earnings history →
RARE Peer Comparison
Ultragenyx Pharmaceutical Inc. (RARE) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RYTM | 6.63B | 96.79 | -31.12 | 45.83% | -93.84% | -204.35% | 1.77 | |
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 |
Compare RARE vs Peers
Ultragenyx Pharmaceutical Inc. (RARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RARE Income Statement
Ultragenyx Pharmaceutical Inc. (RARE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.61M | 51.49M | 103.71M | 271.03M | 351.41M | 363.33M | 434.25M | 560.23M | 673M | 669.43M |
Revenue Growth % | 1863.91% | 1871.48% | 101.41% | 161.32% | 29.66% | 3.39% | 19.52% | 29.01% | 20.13% | 13.33% |
Cost of Goods Sold | 1K | 1.15M | 9.01M | 6.13M | 16.01M | 28.32M | 45.21M | 76.73M | 109M | 109.99M |
COGS % of Revenue | 0.04% | 2.23% | 8.69% | 2.26% | 4.56% | 7.79% | 10.41% | 13.7% | 16.2% | - |
Gross Profit | 2.61M▲ 0% | 50.35M▲ 1828.3% | 94.71M▲ 88.1% | 264.9M▲ 179.7% | 335.4M▲ 26.6% | 335.01M▼ 0.1% | 389.04M▲ 16.1% | 483.5M▲ 24.3% | 564M▲ 16.6% | 559.44M▲ 0% |
Gross Margin % | 99.96% | 97.77% | 91.31% | 97.74% | 95.44% | 92.21% | 89.59% | 86.3% | 83.8% | 83.57% |
Gross Profit Growth % | 101.43% | 1828.34% | 88.1% | 179.71% | 26.61% | -0.12% | 16.13% | 24.28% | 16.65% | - |
Operating Expenses | 331.55M | 421.72M | 518.88M | 595.02M | 717.13M | 983.93M | 958.25M | 1.02B | 1.1B | 1.12B |
OpEx % of Revenue | 12693.45% | 818.96% | 500.3% | 219.54% | 204.08% | 270.81% | 220.67% | 181.97% | 163.3% | - |
Selling, General & Admin | 99.91M | 127.72M | 161.52M | 182.93M | 219.98M | 278.14M | 309.8M | 321.61M | 349M | 350.27M |
SG&A % of Revenue | 3825% | 248.03% | 155.74% | 67.5% | 62.6% | 76.55% | 71.34% | 57.41% | 51.86% | - |
Research & Development | 231.64M | 294M | 357.36M | 412.08M | 497.15M | 705.79M | 648.45M | 697.87M | 750M | 770.95M |
R&D % of Revenue | 8868.45% | 570.93% | 344.56% | 152.04% | 141.48% | 194.26% | 149.33% | 124.57% | 111.44% | - |
Other Operating Expenses | 0 | 3.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -328.94M▲ 0% | -371.37M▼ 12.9% | -424.17M▼ 14.2% | -330.12M▲ 22.2% | -381.74M▼ 15.6% | -648.92M▼ 70.0% | -569.21M▲ 12.3% | -535.97M▲ 5.8% | -535M▲ 0.2% | -561.78M▲ 0% |
Operating Margin % | -12593.49% | -721.18% | -408.98% | -121.8% | -108.63% | -178.6% | -131.08% | -95.67% | -79.49% | -83.92% |
Operating Income Growth % | -32.63% | -12.9% | -14.22% | 22.17% | -15.64% | -69.99% | 12.28% | 5.84% | 0.18% | - |
EBITDA | -323.12M | -351.83M | -415.63M | -317.86M | -368.5M | -630.7M | -543.2M | -500.43M | -500M | -535.77M |
EBITDA Margin % | -12370.48% | -683.24% | -400.75% | -117.28% | -104.86% | -173.59% | -125.09% | -89.33% | -74.29% | -80.03% |
EBITDA Growth % | -32.11% | -8.89% | -18.13% | 23.53% | -15.93% | -71.15% | 13.87% | 7.87% | 0.09% | -12.11% |
D&A (Non-Cash Add-back) | 5.83M | 19.54M | 8.54M | 12.26M | 13.24M | 18.22M | 26.01M | 35.54M | 35M | 26.01M |
EBIT | -318.34M | -197.1M | -398.31M | -152.07M | -423.56M | -658.71M | -542.46M | -504.55M | -535M | -379.36M |
Net Interest Income | 4.07M | 9.54M | 12.1M | -26.25M | -27.49M | -31.94M | -39.32M | -26.54M | -37M | -29.02M |
Interest Income | 4.07M | 9.54M | 13.24M | 7.04M | 1.93M | 11.07M | 26.69M | 36.51M | 25M | 24.17M |
Interest Expense | 0 | 0 | 1.14M | 33.29M | 29.42M | 43.02M | 66M | 63.04M | 62M | 26.19M |
Other Income/Expense | 10.6M | 174.28M | 24.73M | 144.76M | -71.24M | -52.81M | -39.26M | -31.61M | -36M | -43.77M |
Pretax Income | -318.34M▲ 0% | -197.1M▲ 38.1% | -399.44M▼ 102.7% | -185.36M▲ 53.6% | -452.98M▼ 144.4% | -701.73M▼ 54.9% | -608.46M▲ 13.3% | -567.59M▲ 6.7% | -571M▼ 0.6% | -605.54M▲ 0% |
Pretax Margin % | -12187.52% | -382.75% | -385.14% | -68.39% | -128.91% | -193.14% | -140.12% | -101.31% | -84.84% | -90.46% |
Income Tax | -16.2M | 514K | 3.28M | 1.21M | 1.04M | 5.7M | -1.82M | 1.6M | 4M | 1.82M |
Effective Tax Rate % | 5.09% | -0.26% | -0.82% | -0.65% | -0.23% | -0.81% | 0.3% | -0.28% | -0.7% | -0.3% |
Net Income | -302.14M▲ 0% | -197.61M▲ 34.6% | -402.73M▼ 103.8% | -186.57M▲ 53.7% | -454.02M▼ 143.4% | -707.42M▼ 55.8% | -606.64M▲ 14.2% | -569.18M▲ 6.2% | -575M▼ 1.0% | -609.36M▲ 0% |
Net Margin % | -11567.34% | -383.75% | -388.31% | -68.84% | -129.2% | -194.71% | -139.7% | -101.6% | -85.44% | -91.03% |
Net Income Growth % | -22.88% | 34.6% | -103.8% | 53.67% | -143.36% | -55.81% | 14.25% | 6.17% | -1.02% | -10.88% |
Net Income (Continuing) | -302.14M | -197.61M | -402.73M | -186.57M | -454.02M | -707.42M | -606.64M | -569.18M | -575M | -609.36M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 7M | 7M |
EPS (Diluted) | -7.12▲ 0% | -3.97▲ 44.2% | -7.12▼ 79.3% | -3.07▲ 56.9% | -6.70▼ 118.2% | -10.12▼ 51.0% | -8.25▲ 18.5% | -6.29▲ 23.8% | -5.83▲ 7.3% | -6.06▲ 0% |
EPS Growth % | -14.65% | 44.24% | -79.35% | 56.88% | -118.24% | -51.04% | 18.48% | 23.76% | 7.31% | -3.91% |
EPS (Basic) | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | -6.29 | -5.83 | - |
Diluted Shares Outstanding | 42.45M | 49.78M | 56.58M | 60.85M | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M | 100.6M |
Basic Shares Outstanding | 42.45M | 49.78M | 56.58M | 60.85M | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M | 100.6M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RARE Balance Sheet
Ultragenyx Pharmaceutical Inc. (RARE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 244.47M | 522.37M | 851.02M | 1.3B | 856.6M | 883.9M | 732.18M | 817.12M | 951M | 657M |
Cash & Short-Term Investments | 244.47M | 459.71M | 755.23M | 1.2B | 740.2M | 747.76M | 577.21M | 610.02M | 693M | 413M |
Cash Only | 100.49M | 113.43M | 433.58M | 713.53M | 307.58M | 132.94M | 213.58M | 173.73M | 434M | 175M |
Short-Term Investments | 134M | 346.27M | 321.65M | 488.01M | 432.61M | 614.82M | 363.63M | 436.3M | 259M | 238M |
Accounts Receivable | 5.17M | 12.74M | 32.84M | 23.09M | 28.43M | 40.45M | 73.39M | 121.8M | 159M | 121M |
Days Sales Outstanding | 722.73 | 90.3 | 115.59 | 31.1 | 29.53 | 40.63 | 61.69 | 79.36 | 86.23 | 70.76 |
Inventory | 757K | 7.07M | 11.55M | 13.05M | 16.23M | 26.77M | 33.97M | 45.01M | 52M | 55M |
Days Inventory Outstanding | 276.31K | 2.25K | 467.84 | 777.05 | 370.08 | 344.97 | 274.25 | 214.1 | 174.13 | 170.65 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 68.93M | 47.62M | 40.29M | 47M | 68M |
Total Non-Current Assets | 246.28M | 197.19M | 284.48M | 464.25M | 665.79M | 661.54M | 758.83M | 686.33M | 581M | 639M |
Property, Plant & Equipment | 21.84M | 20.05M | 74.68M | 114.04M | 176.18M | 259.73M | 290.57M | 265.93M | 267M | 239M |
Fixed Asset Turnover | 0.12x | 2.57x | 1.39x | 2.38x | 1.99x | 1.40x | 1.49x | 2.11x | 2.52x | 2.65x |
Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44M | 44M |
Intangible Assets | 141.54M | 129.22M | 129M | 131.11M | 130.79M | 160.1M | 166.27M | 178.31M | 176M | 174M |
Long-Term Investments | 9.97M | 1.82M | 32.93M | 165.88M | 293.86M | 148.97M | 199.9M | 135M | 59M | 132.52M |
Other Non-Current Assets | 3.41M | 3.51M | 3.47M | 8.81M | 20.56M | 48.34M | 57.69M | 62.68M | 35M | 182M |
Total Assets | 490.75M▲ 0% | 719.56M▲ 46.6% | 1.14B▲ 57.8% | 1.76B▲ 55.0% | 1.52B▼ 13.5% | 1.55B▲ 1.5% | 1.49B▼ 3.5% | 1.5B▲ 0.8% | 1.53B▲ 1.9% | 1.3B▲ 0% |
Asset Turnover | 0.01x | 0.07x | 0.09x | 0.15x | 0.23x | 0.24x | 0.29x | 0.37x | 0.44x | 0.50x |
Asset Growth % | -9.22% | 46.62% | 57.8% | 54.96% | -13.48% | 1.51% | -3.52% | 0.83% | 1.9% | -41.22% |
Total Current Liabilities | 71.01M | 74.72M | 103.3M | 189.61M | 181.37M | 261.21M | 280.44M | 344.15M | 384M | 325M |
Accounts Payable | 8.89M | 12.28M | 12.87M | 12.92M | 17.14M | 43.27M | 42.11M | 38.76M | 31M | 42M |
Days Payables Outstanding | 1000K | 3.91K | 521.53 | 769.6 | 390.77 | 557.73 | 340.01 | 184.36 | 103.81 | 122.63 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 81M | 0 |
Deferred Revenue (Current) | 5.99M | 0 | 0 | 59.22M | 7.61M | 1.48M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 142.79M | 87.47M | 183M | 283M |
Current Ratio | 3.44x | 6.99x | 8.24x | 6.83x | 4.72x | 3.38x | 2.61x | 2.37x | 2.48x | 2.02x |
Quick Ratio | 3.43x | 6.90x | 8.13x | 6.76x | 4.63x | 3.28x | 2.49x | 2.24x | 2.34x | 1.85x |
Cash Conversion Cycle | -1000K | -1.57K | 61.9 | 38.54 | 8.85 | -172.13 | -4.07 | 109.09 | 156.55 | 118.78 |
Total Non-Current Liabilities | 36.28M | 35.92M | 378.43M | 415.57M | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B | 1.2B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.17B | 0 |
Capital Lease Obligations | 0 | 0 | 29.76M | 39.25M | 30.9M | 19.81M | 30.57M | 30.04M | 24M | 70.22M |
Deferred Tax Liabilities | 31.17M | 31.17M | 33.31M | 33.31M | 33.31M | 31.67M | 0 | 30.06M | 30M | 120.12M |
Other Non-Current Liabilities | 5.12M | 4.76M | 315.37M | 335.67M | 352.79M | 880.26M | 904.59M | 836.91M | -4M | 1.17B |
Total Liabilities | 107.3M | 110.65M | 481.73M | 605.18M | 599.84M | 1.19B | 1.22B | 1.24B | 1.6B | 1.52B |
Total Debt | 0 | 0 | 36.99M | 48.23M | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B | 0 |
Net Debt | -100.49M | -113.43M | -396.59M | -665.3M | -265.61M | -101.35M | -170.41M | -133.39M | 842M | -175M |
Debt / Equity | - | - | 0.06x | 0.04x | 0.05x | 0.09x | 0.16x | 0.15x | - | -0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.33x |
Interest Coverage | - | - | -350.93x | -4.57x | -14.40x | -15.31x | -8.22x | -8.00x | -8.63x | -14.49x |
Total Equity | 383.45M▲ 0% | 608.91M▲ 58.8% | 653.76M▲ 7.4% | 1.15B▲ 76.6% | 922.56M▼ 20.1% | 352.49M▼ 61.8% | 275.41M▼ 21.9% | 262.3M▼ 4.8% | -73M▼ 127.8% | -229M▲ 0% |
Equity Growth % | -19.1% | 58.8% | 7.37% | 76.57% | -20.08% | -61.79% | -21.87% | -4.76% | -127.83% | -538.07% |
Book Value per Share | 9.03 | 12.23 | 11.56 | 18.97 | 13.61 | 5.04 | 3.74 | 2.90 | -0.74 | -2.28 |
Total Shareholders' Equity | 383.45M | 608.91M | 653.76M | 1.15B | 922.56M | 352.49M | 275.41M | 255.3M | -80M | -236M |
Common Stock | 44K | 51K | 58K | 67K | 69K | 70K | 82K | 92K | 0 | 0 |
Retained Earnings | -832.67M | -1.03B | -1.43B | -1.62B | -2.07B | -2.78B | -3.39B | -3.96B | -4.53B | -4.72B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -432K | -3.59M | -8M | 0 |
Accumulated OCI | -5.68M | -633K | -147K | 689K | -1.4M | -6.57M | 647K | -643K | 9M | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 7M | 7M |
RARE Cash Flow Statement
Ultragenyx Pharmaceutical Inc. (RARE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -253.84M | -290.57M | -345.38M | -132.22M | -338.69M | -380.46M | -474.81M | -414.19M | -466M | -496.52M |
Operating CF Margin % | -9718.34% | -564.26% | -333.01% | -48.78% | -96.38% | -104.72% | -109.34% | -73.93% | -69.24% | - |
Operating CF Growth % | -57.69% | -14.47% | -18.87% | 61.72% | -156.16% | -12.33% | -24.8% | 12.77% | -12.51% | -121.05% |
Net Income | -302.14M | -197.61M | -402.73M | -186.57M | -454.02M | -707.42M | -606.64M | -569.18M | -575M | -609.36M |
Depreciation & Amortization | 5.83M | 19.54M | 8.54M | 12.26M | 13.24M | 18.22M | 26.01M | 35.54M | 0 | -4.16M |
Stock-Based Compensation | 68.01M | 80.11M | 82M | 85.73M | 104.95M | 130.38M | 135.21M | 158.03M | 153M | 143.54M |
Deferred Taxes | -16.25M | -167.65M | -18.94M | -169.78M | 48.67M | 0 | -1.62M | 0 | 0 | 0 |
Other Non-Cash Items | 10.93M | -156K | 1.69M | 21.46M | 11.71M | 118.12M | -12.67M | -52.5M | -21M | -60.17M |
Working Capital Changes | -20.23M | -24.79M | -15.94M | 104.66M | -63.24M | 60.23M | -15.1M | 13.92M | -23M | 33.63M |
Change in Receivables | -5.17M | -7.58M | -20.1M | 9.84M | -5.43M | -12.07M | -22.78M | -33.6M | -31M | -22.06M |
Change in Inventory | -757K | -5.28M | -4.45M | -1.35M | -3.12M | -9.7M | -6.93M | -11.21M | -6M | -9.24M |
Change in Payables | 3.46M | 3.37M | 20.65M | 29.6M | 2.81M | 79.84M | 2.38M | 46.99M | 24M | 15.45M |
Cash from Investing | 56.42M | -33.33M | -13.04M | -179.12M | -195.37M | -291.65M | 168M | -17.77M | 236M | 67.11M |
Capital Expenditures | -2.79M | -4.08M | -24.83M | -43.91M | -73.09M | -116.12M | -44.27M | -7.49M | 0 | -4.74M |
CapEx % of Revenue | 106.93% | 7.92% | 23.94% | 16.2% | 20.8% | 31.96% | 10.19% | 1.34% | 0.89% | 0.71% |
Acquisitions | -142.8M | 0 | -11.79M | 0 | 0 | -75.03M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 934K | 170.32M | 11.79M | -5.55M | -942K | -30.84M | -7.55M | -14.94M | 236M | 40.91M |
Cash from Financing | 136.27M | 336.85M | 679.31M | 600.27M | 118.55M | 501.21M | 388.14M | 399.24M | 478M | 477.84M |
Debt Issued (Net) | -4.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 392M | 392M |
Equity Issued (Net) | 131.96M | 309.02M | 355.24M | 511.21M | 78.94M | 0 | 379.75M | 380.98M | 86M | 85.84M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 9.25M | 27.83M | 324.06M | 89.06M | 39.61M | 501.21M | 8.39M | 18.26M | 0 | 0 |
Net Change in Cash | -60.63M▲ 0% | 12.48M▲ 120.6% | 320.72M▲ 2469.0% | 290.05M▼ 9.6% | -416.71M▼ 243.7% | -171.98M▲ 58.7% | 81.8M▲ 147.6% | -35.24M▼ 143.1% | 253.47M▲ 819.3% | 50.18M▲ 0% |
Free Cash Flow | -256.64M▲ 0% | -294.64M▼ 14.8% | -370.21M▼ 25.6% | -176.13M▲ 52.4% | -411.79M▼ 133.8% | -526.59M▼ 27.9% | -521.57M▲ 1.0% | -421.68M▲ 19.2% | -472M▼ 11.9% | -487.2M▲ 0% |
FCF Margin % | -9825.27% | -572.18% | -356.96% | -64.98% | -117.18% | -144.93% | -120.11% | -75.27% | -70.13% | -72.78% |
FCF Growth % | -49.94% | -14.81% | -25.65% | 52.43% | -133.8% | -27.88% | 0.95% | 19.15% | -11.93% | -17.95% |
FCF per Share | -6.05 | -5.92 | -6.54 | -2.89 | -6.07 | -7.53 | -7.09 | -4.66 | -4.79 | -4.84 |
FCF Conversion (FCF/Net Income) | 0.84x | 1.47x | 0.86x | 0.71x | 0.75x | 0.54x | 0.78x | 0.73x | 0.81x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RARE Key Ratios
Ultragenyx Pharmaceutical Inc. (RARE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -70.48% | -39.83% | -63.79% | -20.64% | -43.72% | -110.96% | -193.23% | -211.71% | -607.51% | 1910.91% |
Return on Invested Capital (ROIC) | -82.81% | -71.56% | -84.54% | -66.36% | -49.96% | -107.19% | -239.74% | -343.71% | -89.37% | -155.75% |
Gross Margin | 99.96% | 97.77% | 91.31% | 97.74% | 95.44% | 92.21% | 89.59% | 86.3% | 83.8% | 83.57% |
Net Margin | -11567.34% | -383.75% | -388.31% | -68.84% | -129.2% | -194.71% | -139.7% | -101.6% | -85.44% | -91.03% |
Debt / Equity | - | - | 0.06x | 0.04x | 0.05x | 0.09x | 0.16x | 0.15x | - | -0.00x |
Interest Coverage | - | - | -350.93x | -4.57x | -14.40x | -15.31x | -8.22x | -8.00x | -8.63x | -14.49x |
FCF Conversion | 0.84x | 1.47x | 0.86x | 0.71x | 0.75x | 0.54x | 0.78x | 0.73x | 0.81x | 0.80x |
Revenue Growth | 1863.91% | 1871.48% | 101.41% | 161.32% | 29.66% | 3.39% | 19.52% | 29.01% | 20.13% | 13.33% |
Related:RARE Dividend History·RARE Revenue History·RARE Price History·RARE P/E History·RARE Financial Ratios·RARE Institutional Holders
RARE SEC Filings & Documents
Ultragenyx Pharmaceutical Inc. (RARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
RARE Frequently Asked Questions
Ultragenyx Pharmaceutical Inc. (RARE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ultragenyx Pharmaceutical Inc. (RARE) reported $669.4M in revenue for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. (RARE) grew revenue by 20.1% over the past year. This is strong growth.
Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $609.4M for fiscal year 2025.
Dividend & Returns
Ultragenyx Pharmaceutical Inc. (RARE) has a return on equity (ROE) of -607.5%. Negative ROE indicates the company is unprofitable.
Ultragenyx Pharmaceutical Inc. (RARE) had negative free cash flow of $487.2M in fiscal year 2025, likely due to heavy capital investments.